Tulane University is actively seeking companies interested in commercializing novel compounds which are effective antagonists of ghrelin, growth hormone releasing peptide and the growth hormone secretagogue receptor.
Provides effective inhibition of hormonal pathways directly associated with appetite. Indications that can be treated by these compounds include obesity, diabetes (Type I and Type II), metabolic syndrome, hypertension and treatment of breast, prostate and pituitary tumors, among others.
These peptide compounds are relatively short (less than 10 amino acids) and act at the level of the central nervous system. Peptides are generally easy to manufacture and purify and tend to have very low toxicity profiles.
This technology has been tested extensively in vitro and in vivo in a rat model, with results strongly supporting the anti-obesity and anti-diabetes applications. Laboratory work is ongoing to produce more effective species of these compounds.
Cyril Bowers, Ph.D., David Coy, Ph.D., Simon Hocart, Ph.D., Gloria Tannenbaum, Ph.D.
Tulane Technology Transfer and Intellectual Property Development, New Orleans, LA 70112 504-988-6962 email@example.com